MedTrace Logo

In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?

NCT03174912 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2017-06-05

No results posted yet for this study

Summary

Investigators aimed to evaluate the performance of The European Organization for Research and Treatment of Cancer(EORTC) and the Spanish Urology Association for Oncological Treatment(CUETO) risk tables on all non-muscle invasive bladder cancer patients(NMIBC), and those not treated with BCG and treated with BCG separately.

Conditions

Interventions

PROCEDURE

Intravesical BCG instillation

ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer

Sponsors & Collaborators

  • Ankara Training and Research Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-01
Primary Completion
2016-12-31
Completion
2016-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03174912 on ClinicalTrials.gov